Mumbai, India (PressExposure) July 18, 2011 -- Enhancing product portfolio of 110 diversified brands
Hetero Healthcare Limited, a leading Indian multi-national drug manufacturer, announced today the launching of KUTUB across India. KUTUB is now available at medical stores all over India.
Dapoxetine, the generic name of KUTUB, is the world's first and only drug in the pharmaceutical market for on-demand use in Premature Ejaculation (PE). Considering the extensive worldwide trials for Dapoxetine and their successful results, Hetero has introduced this drug in India. It heralds a new beginning in the treatment of PE as Dapoxetine is a unique medicine (tablet), designed to be taken only when needed, that is 1-3 hours before anticipated intimate activity. The drug is being manufactured for the Indian market at the award winning manufacturing facilities of Hetero in the country.
Premature Ejaculation, also known as rapid ejaculation or early ejaculation is a very common sexual problem, affecting 30%-60% of male population across the globe. "In India PE is very common but underreported for various socio-economic reasons. This new launch of Hetero is a significant milestone of scientific treatment for PE," said Srinivas Reddy, Marketing Director, Hetero. "Given the growing population pursuing stressful professional careers, this kind of scientific treatment holds tremendous promise for this largely underreported problem."
The launching of Kutub has strengthened the product portfolio of Hetero further with a strong line up of 110 diversified brands. Hetero visualizes itself as an aggressive player in the global pharmaceutical scenario supplying products developed combining intellectual property, research strengths and strong human resource inputs.
Availability & Price of Kutub:
Available on doctor's prescription at medical stores all over the country
Price is Rs. 79.00 for 4 tablets pack of Kutub 30 mg and Rs. 149.00 for 4 tablets pack of Kutub 60 mg
About Hetero Healthcare Limited:
Hetero Healthcare Ltd., a part of Hetero Drugs, has been at the frontlines of process development for manufacture of latest drug molecules and has recently been the largest supplier of Oseltamivir to the Govt. of India during the H1N1 pandemic.
With various manufacturing facilities being supported by excellent infrastructure and compliance to the GMP requirements, Hetero Healthcare manufactures and markets its products in over 100 countries in Asia, Middle-east, Eastern Europe, Latin America, United States, Canada and Europe.
Hetero received National Award for Best Efforts in Research and Development from the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India, in the year 1996 and Highest Exporter award for the year 1999.
For more information, please visit http://www.heterodrugs.com